Literature DB >> 11576343

Increased expression of heparanase in puromycin aminonucleoside nephrosis.

V Levidiotis1, J Kanellis, F L Ierino, D A Power.   

Abstract

BACKGROUND: The beta-D-endoglycosidase heparanase has been proposed as an important contributor to loss of glomerular charge in proteinuria. Expression of heparanase was, therefore, determined in acute puromycin aminonucleoside (PAN) nephrosis.
METHODS: A rabbit polyclonal antibody was produced against a 17-amino acid peptide derived from the predicted amino acid sequence of heparanase. The antibody was validated by Western blot. Immunohistochemical staining and Western blotting were used to localize heparanase protein in normal kidneys and kidneys from rats with PAN nephrosis. Northern blot analysis was used to determine mRNA expression.
RESULTS: Immunohistochemical staining showed that heparanase protein was localized to tubular cells in the distal convoluted tubules, thick ascending limb of the loop of Henle, and transitional cell epithelium in normal kidney. Minimal expression was noted in normal glomeruli. Western blot analysis of protein from isolated normal glomeruli showed minimal expression of the 65 kD proheparanase protein. A marked increase in the staining for heparanase was found at day 5 of the PAN nephrosis model, at approximately the time of onset of proteinuria, and at day 14. Expression was predominantly seen in podocytes. At day 5, only the 65 kD proheparanase species was identified, but at day 14, mature 58 kD heparanase also was present. Northern blot analysis of sieved glomeruli at day 14 confirmed an increase in heparanase mRNA. The human podocyte cell line 56/10A1 also produced both proheparanase and mature heparanase, suggesting that podocytes can activate heparanase without other cell types.
CONCLUSION: The previously mentioned data confirm that the novel beta-D-endoglycosidase heparanase is up-regulated and activated in glomeruli from rats with proteinuria. Heparanase may be involved, therefore, in the loss of glomerular charge seen in proteinuria. Moreover, the presence of heparanase in normal tubules suggests that it may also be involved in cell migration or turnover.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576343     DOI: 10.1046/j.1523-1755.2001.00934.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Pathogenesis of proteinuria: lessons learned from nephrin and podocin.

Authors:  Hannu Jalanko
Journal:  Pediatr Nephrol       Date:  2003-06       Impact factor: 3.714

2.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

Review 3.  Tumorigenic and adhesive properties of heparanase.

Authors:  Flonia Levy-Adam; Neta Ilan; Israel Vlodavsky
Journal:  Semin Cancer Biol       Date:  2010-07-07       Impact factor: 15.707

4.  Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment.

Authors:  Itay Shafat; Ayelet Ben Barak; Sergey Postovsky; Ronit Elhasid; Neta Ilan; Israel Vlodavsky; Miriam Weyl Ben Arush
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

5.  Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy.

Authors:  T J M Wijnhoven; M J W van den Hoven; H Ding; T H van Kuppevelt; J van der Vlag; J H M Berden; R A Prinz; E J Lewis; M Schwartz; X Xu
Journal:  Diabetologia       Date:  2007-12-06       Impact factor: 10.122

6.  Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats.

Authors:  Shan Chen; Zhan Fang; Zhonghua Zhu; Anguo Deng; Jianshe Liu; Chun Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

7.  Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function.

Authors:  Itay Shafat; Amir Agbaria; Mona Boaz; Doron Schwartz; Ronny Baruch; Richard Nakash; Neta Ilan; Israel Vlodavsky; Talia Weinstein
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

8.  Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels.

Authors:  Itay Shafat; Neta Ilan; Samih Zoabi; Israel Vlodavsky; Farid Nakhoul
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

9.  Nephroprotective effect of heparanase in experimental nephrotic syndrome.

Authors:  Suheir Assady; Joel Alter; Elena Axelman; Yaniv Zohar; Edmond Sabo; Michael Litvak; Marielle Kaplan; Neta Ilan; Israel Vlodavsky; Zaid Abassi
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 10.  Mammalian heparanase: what is the message?

Authors:  Veronique Vreys; Guido David
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.